Pharmaceuticals DC $500K+ Reviewed

Barda Drive Ez-baa (ezbaa - 22-100-sol-00003)

HHS

WASHINGTON, DC

vaccines on demand host-directed therapeutics host-based diagnostics medical countermeasures lung therapeutics $500K+

Posted Feb 3, 2023

Due Oct 18, 2027

Description

The BARDA DRIVe EZ-BAA (EZ-BAA-22-100-SOL-00003), issued by HHS, solicits research and development proposals across multiple Areas of Interest (AOIs) focused on innovative medical countermeasures, including ReDIRECT, Lab at Home, Digital MCMs, Host-Directed Therapeutics, Healing Lungs, DRIVe Forward, Vaccines on Demand, ReBooT, Host-Based Diagnostics, and REPAIR. These AOIs target advanced technologies for diagnostics, therapeutics, vaccines, and lung health solutions to address public health threats. Eligible bidders include biotechnology firms, pharmaceutical companies, academic researchers, and medical device developers with expertise in rapid-response medical product innovation.

A strong match for healthcare vendors

Curated for medical & healthcare suppliers

Why we classified this as medical

BARDA (Biomedical Advanced Research and Development Authority) under HHS is issuing this EZ-BAA for medical countermeasures (MCMs) R&D, with AOIs explicitly covering vaccines on demand, digital MCMs, host-directed therapeutics, healing lungs, and host-based diagnostics. These areas directly target pharmaceuticals, vaccines, diagnostics, and therapeutics for public health emergencies, aligning with medical procurement needs.

View Original Source

Save for Later

Send to Pipeline

Closing date unconfirmed

This bid lists a closing date of Oct 18, 2027, which is more than a year out — almost certainly a data error from the source. Treat the deadline as unknown.

Please confirm the actual deadline on the original source before you rely on it.

Check the source